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Editor: Mohandas NarlaΒeta-thalassemia, is a hemoglobinopathy characterized by reduced beta-globin chain synthesis, leading to imbal-
anced globin chain production, ineffective erythropoiesis and anemia. Increasing gamma-globin gene expression
is a promising therapeutic approach as it reduces this imbalance by combining with the excess alpha globin
chains and producing fetal hemoglobin (HbF). Furthermore, increased iron absorption and repeated blood trans-
fusions lead to iron overload and tissue damage secondary to reactive oxygen species. Compounds exhibiting
both antioxidant and HbF inducing activities are, therefore, highly desirable therapeutic agents. Resveratrol,
a natural phytoalexin, combines these two activities but is also cytotoxic. Nine hydroxystilbenic resveratrol
derivatives were synthesized in an attempt to identify compounds that retain the HbF-inducing and antioxidant
activities of resveratrol but exhibit reduced cytotoxicity. Three derivatives (P1, P4 and P11) exhibited similar
hemoglobin-inducing properties to resveratrol in K562 cells, however, only P11 showed reduced cytotoxicity.
All three derivatives demonstrated variable HbF-inducing activity in primary erythroid progenitor cells from
healthy donors. Resveratrol and P11 increased HbF induction signiﬁcantly, with P11 having the highest activity.
Additionally, P4 signiﬁcantly increased progenitor numbers. A combinatorial treatment in K562 cells using
resveratrol and decitabine resulted in a statistically signiﬁcant increase in hemoglobin-inducing activity only
above the level shown by resveratrol alone.






Βeta-thalassemia, a global health burden, is an inherited disorder of
beta globin chain production. The disease is characterized by reduced
synthesis of functional β-globin chains, leading to imbalanced globin
chain ratio, ineffective erythropoiesis and anemia [1]. As a result,
thalassaemic patients require regular blood transfusions with regular
iron chelation therapy as a means of managing the disease. However,
this treatment is not curative and still has substantial morbidity. A
very promising therapeutic approach for β-thalassemia is the produc-
tion of fetal hemoglobin (HbF) through pharmacological reactivation
of endogenous gamma-globin genes as γ-globin can substitute for the
absent or reduced adult β-globin [2,3]. The currently available HbF-
inducing chemical agents have limited clinical application due to their
moderate therapeutic properties and potential cytotoxic effects [4,5].ology and Genetics, Molecular
Ayios Dhometios, 2370 Nicosia,
.Therefore, identiﬁcation of novel agentswith higher HbF inducing activ-
ity and lower cytotoxicity has been one of themajor challenges over the
past few years.
Oxidative stress has been observed in various types of thalassemia as
well as in other hereditary and acquired hemolytic anemias. This can be
mainly attributed to iron overload due to increased iron absorption in
the gastrointestinal tract [6], multiple blood transfusions as well as to
increased intracellular denaturation of imbalanced hemoglobin subunits
resulting in dissociation of heme from globin and iron from heme [7,8].
Labile non-transferrin bound iron can be involved in chemical reactions
that generate reactive oxygen species (ROS) that affect various cellular
components, particularly the cell membrane, damaging vital organs in-
cluding the heart, liver and endocrine system [9]. In addition, endoge-
nous antioxidant mechanisms are depleted due to the increased need
to neutralize the oxidative stress [10]. Oral administration of vitamin E
in transfusion-independent beta-thalassemia patients was shown to de-
crease ROS production and increase glutathione reductase levels in red
blood cells [11]. Moreover, natural antioxidants such as curcuminoids
[12] and fermented papaya preparation [13] were studied for their po-
tential use towards elimination of antioxidant stress.
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dietary products such as in the skin of red grapes, peanuts and red
wine as well as in medicinal plants where it is produced in response
to infection or other stresses. Resveratrol was originally isolated in
1940 from the root of Veratrum grandiﬂorum, a poisonous medicinal
plant [14] known for its antimicrobial activity. However, it was not
until the beginning of 1990 that research into resveratrol intensiﬁed
due to evidence of the cardioprotective effects of red wine [15]. Since
the 1990s, growing evidence from several studies has been accumu-
lating showing resveratrol to have many biological activities including
anti-inﬂammatory [16], anti-proliferative [17], chemopreventive [18,19],
antioxidant [20,21] and lifespan enhancing activities [22–24], while
having the ability to limit or prevent progression of cerebral ischemic
injuries, cardiovascular injuries [25,26], cancer progression [11,18,27],
arthritis [28,29], diabetes [30], neurodegernerative disorders [31,32]
and a number of other aging-associated and stress resistance disorders.
The mechanisms by which resveratrol is able to exert such a wide
range of effects is not fully understood, but studies have led to the iden-
tiﬁcation of a large number of direct targets for this compound. However,
a number of its biological actions have been attributed to its antioxidant
properties.
Apart from its antioxidant activities, resveratrol was found to inhibit
ribonucleotide reductase in the same manner as hydroxyurea, the well
known HbF inducer, as well as to promote erythroid differentiation
[33]. Fibach et al. [34] were the ﬁrst to show that resveratrol, in addition
to its antioxidant activity, can also stimulate the expression of γ-globin
genes and increase fetal hemoglobin production. In the current study,
we investigated the ability of resveratrol and nine newhydroxystilbenic
derivatives as potential HbF-reactivating agents aswell as the combined
effect of resveratrol and decitabine, another known HbF-inducer, as po-
tential therapeutic approaches for β-thalassemia.Fig. 1. Structures of the nine hydroxystilbenic derivativeanalogs to resveratrol alo2. Material and methods
2.1. Materials
Resveratrol (3,4′,5-trihydroxystilbene) was purchased from Sigma
(St Louis, USA). The nine resveratrol analogswere designed and synthe-
sized by Perkins condensation following the procedure described else-
where [35]. The purity of each compound (N97%) was controlled by
HPLC.
2.2. Preparation of agents
Stock solutions of all compounds were prepared in 100% methanol
and kept at−20 °C. Theworking solutionswere prepared in 50%meth-
anol. The chemical structures of the compounds tested are shown in
Fig. 1.
2.3. Culture of human K562 cell line and analysis of cell differentiation
The human erythroleukemic cell line K562 was maintained in RPMI
medium (Gibco, Invitrogen Inc., Paisley, UK) enriched with 10% FBS
(Gibco, Invitrogen Inc., Paisley, UK), 0.6% Glutamine (Gibco, Invitrogen
Inc., Paisley, UK) and 50 U/ml of Penicillin/Streptomycin (Gibco,
Invtrogen Inc., Paisley, UK). The cells were kept at 37 °C with 5% CO2
in a humiﬁed environment. Varying concentrations of each agent
under investigation were added in 2 × 104 cells/ml. Cell survival mea-
sured by Trypan blue (Sigma, St. Louis, USA) and the Hb inducing ability
of each agent measured by Benzidine staining were investigated for
all derivatives after 5 days of treatment. Un-treated cells were used as
negative control and cells treated with 150 μMHydroxyurea as positiveng with resveratrol, the parent compound, which is commercially available.
Table 1
Investigation of the hemoglobin inducing ability (Benzidine stain) and cytotoxicity
(Trypan blue) of each resveratrol derivative in theK562 cell line. The concentration of each
agent resulting in approximately 50% cell survival and the corresponding effect in hemo-
globin production is presented. 150 μMHydroxyurea was used as a positive control in all
experiments. The values shown represent the average of three experiments.
K562 cell line
Agent Concentration Cell survival Benzidine stain
(ﬁM) (% relative to
uninduced control)
(fold increase relative to
un-induced control)
Un-treated – 100 1
HU 150 38.9 4.78
PI 5 43 3.8
P2 5 48.8 2.3
P3 5 44 2.8
P4 5 48 2.9
P5 20 65.5 2.56
P7 20 41.2 2.86
P8 20 48.9 1.9
P9 5 51.7 1.9
Pll 10 52 3.3
Resveratrol 5 47.3 5.7
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tion studied were performed.
2.4. Benzidine test
Stock benzidine solution was prepared by the addition of 1 g benzi-
dine dihydrochloride (Sigma Aldrich, St. Louis, USA) in 14.5 ml glacial
acetic acid to 485.3 ml of distilled water. The working solution was
prepared by the addition of 20 μl of 30% H2O2 to 1 ml of benzidine
stock solution. Equal volumes of theworking solution and cells are com-
bined and allowed to stand at room temperature for 2–3min. Hemoglo-
bin (Hb) containing cells are stained blue and can be scored using a
hemocytometer.
2.5. Primary human erythroid cultures from healthy donors
Human erythroid progenitor cellswere cultured using the twophase
liquid culture as previously described [36]. Brieﬂy, mononuclear cells
were isolated from buffy coats of healthy donors obtained from the
Nicosia Blood bank by Lympholyte (Tebu-Bio, Le-Perray-en-Yvelines
France) density gradient centrifugation separation. The layer of mono-
nuclear cells was seeded in α-ΜΕΜ (Sigma Aldrich, St. Louis, USA) sup-
plemented with 10% Fetal Bovine serum (FBS) (Not heat inactivated)
(Gibco, Invitrogen Inc., Paisley UK) 10% conditioned medium from the
H5637 bladder carcinoma cell line and 1 μg/ml cyclosporin A (Sigma
Aldrich, St. Louis, USA). On day 7 of incubation in Phase I, non-
adherent cells were re-suspended in α-MEM (Sigma Aldrich, St. Louis,
USA) supplemented with 5 U/ml/5 μg/ml penicillin/streptomycin, 10%
FBS (Gibco, Invitrogen Inc., Paisley UK), 1 μg/ml cyclosporin A, 10%
conditioned medium from cultures of H5637 bladder carcinoma cell
line, 10 ng/ml stem cell factor (Gibco, Invitrogen Inc., Paisley UK) and
1U/ml EPO. This constitutes the start of Phase II of the primary erythroid
cultures.
2.6. Treatment of human primary erythroid progenitor cells
For the study of potential HbF inducers, compounds were added to
the primary erythroid cell cultures on day 6 of Phase II. Human primary
erythroid progenitor cell were seeded at ~1.5–2.0 × 106 cells/ml and
different amounts of the compounds to be studied were added. Cells
without any agent added (un-treated samples) were used as negative
controls, and cells treated with 150 μM Hydroxyurea (Sigma Aldrich,
St. Louis, USA) were used as positive controls. Cell counts and benzidine
stainingwere performed on all samples afterﬁve days of treatmentwith
the agents. HbF levels were determined by cation exchange high perfor-
mance liquid chromatography (HPLC).
2.7. Cation exchange high performance liquid chromatography (HPLC)
The levels of HbF in primary erythroid cultures were determined by
HPLC [37] using the Schimadzu Instrument (Kyoto, Japan) with DGUA5
degasser, LC-20AD pump, SIL-20AC HT autosampler, SPD-M20A PDA
detectors and CTO-20A oven. Hemoglobinswere separated on a PolyCat
Atm 35 × 4.6 mm, 5 μm, 1000 A column (PolyLC Inc., Columbia, USA).
The samples were eluted with a gradient of Bis-Tris-KCN-NaCl buffers
and hemoglobins were detected at 417 nm.
3. Results
Initially resveratrol was screened in vitro in K562 cells. K562 cells are
multipotential, hematopoietic, malignant cells that have the ability
to reproducibly provide a large, uniform, population of cells that exhibit
a stable and synchronized pattern of differentiation in the presence of
chemical inducers such as hemin [38]. It is this innate ability to produce
hemoglobin, their immortality and accessibility that renders K562 cells
the most highly used model as a ﬁrst line screen of potential agents.Screening of the agent in K562 cells showed resveratrol to be a highly
active Hb-inducing agent resulting in a 5.7-fold increase in the number
of hemoglobin containing cells and 50% cell survival relative to the un-
treated sample when used at 5 μM (Table 1). This was higher than the
average effect observed with 150 μM hydroxyurea [39], the positive
control compound which showed an average of 4.78-fold increase in
the number of Hb-positive cells at a concentration 30-fold higher than
resveratrol (Table 1). However, resveratrolwas found to be slightly cyto-
toxic with cell survival reduced to ~35% at 10 μM relative to the un-
treated control. Therefore, the use of resveratrol might be limited due
to this cytotoxicity. As a result, nine hydroxystilbenic resveratrol deriva-
tives were designed and synthesized, with the aim of identifying an
agent that retains this potentHb inducing activity but has lower cytotox-
icity than resveratrol. All nine derivatives had the same backbone struc-
ture as the parent compound but had small substitutions on the othro,
meta and para positions of the two aromatic rings (Fig. 1). Initial screen-
ing of the nine derivatives was performed in K562 cells where the effect
of a number of different concentrations of each derivative was investi-
gated after ﬁve days of incubation with the agents (Supplementary).
For each derivative, the concentration with the highest Hb inducing ac-
tivity, while still maintaining a 40–50% cell survival, is shown in Table 1.
Only three derivatives (P1, P4 and P11) exhibited Hb inducing activity
comparable to the parent compound, with a fold increase in the percent-
age of Hb containing cells relative to the un-treated control of 3.8,
2.9 and 3.3 respectively. Among the latter three compounds, P11 had
the lowest cytotoxicity while maintaining comparable hemoglobin-
inducing activity to the rest of the compounds. This difference in cyto-
toxicity was apparent at concentrations of 5 μM and above (Fig. 2).
Derivatives P1, P4 and P11 along with resveratrol, were further
studied in primary human erythroid cultures from healthy donors.
HPLC analysis, which can detect speciﬁcally the levels of HbF in the sam-
ple, showed that individual cultures do not respond to the same extent
to the each agent. Therefore, the cultures were divided into responders
and non-responderswith respect to HbF production following exposure
to each test chemical. Cultures which responded to a chemical (at
any test concentration) with an increase in HbF production of more
than 10%were classed as responders to that chemical while the remain-
der of the cultures was classed as non-responders. Responders to res-
veratrol (n = 5) demonstrated a 33% increase in HbF levels at 1 μM of
resveratrol, an effect that was statistically signiﬁcant (p-value b 0.05).
Similarly, responders to P11 (n = 6) demonstrated a 40 and 32%
increase in HbF above the un-treated control at concentrations of
0.01 and 0.05 μM respectively. These increases were also statistically
signiﬁcant (p-value b 0.05). Interestingly, non-responders to both
Fig. 2. Investigation of hemoglobin inducing activity (A) and cytotoxicity (B) of compounds P1, P4, P11 and resveratrol for a range of concentrations in K562 cells. P1, P4 and P11 showed
hemoglobin induction levels similar to resveratrol, the parent compound,with P11 being the least cytotoxic. The results are the average of three experimentswith error bars corresponding
to the standard deviation.
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cant reduction in HbF levels when compared to the un-treated controls
(p-value b 0.05, paired t-test) at 0.01 μM of resveratrol and at 0.05–
10 μM of P11 (Fig. 3). Responders to P4 (n = 8) generated no statisti-
cally signiﬁcant changes in the response to the agent.
Resveratrol, derivatives P4 and P11 were shown to be less toxic in
primary human erythroid cultures than in K562 cells with nomajor re-
duction in cell survival for concentrations below 20 μM for resveratrol
and P4 and for any concentration tested for P11, in both responders
and non-responders (Figs. 3 & 4). P1 showed higher cytotoxicity than
resveratrol with cell survival dropping to b50% at concentrations of
5 μM and above. P1 was therefore considered inappropriate as a thera-
peutic HbF inducer. Interestingly, treatment with 0.1 μM concentrationFig. 3. Treatment of primary human erythroid cultures from healthy donors with Resveratrol (
(A+C) and non-responders (B+D) to each agent based on a 10% increase threshold inHbF per
5–7 cultures. Error bars correspond to the standard deviation. Statistically signiﬁcant changes iof derivative P4 in responders and 0.01 μM of P4 in non-responders, in-
creased cell numbers signiﬁcantly (p-value b 0.05, paired t-test) above
those observed with methanol alone, an effect that was not observed
with P11 or resveratrol, suggesting a proliferative role at low concentra-
tions of the agent.
The concurrent application of several HbF inducers is seen as a pos-
sible method that would allow synergistic enhancement of their indi-
vidual activities [40]. Therefore, the combined use of resveratrol with
decitabine, a knownHbF inducing agent, was investigated as an alterna-
tive therapeutic approach as their simultaneous use could combine the
antioxidant activity of resveratrol with the strong HbF inducing activity
of decitabine. The combined use of decitabine with resveratrol in K562
cells (Fig. 5) increased hemoglobin production signiﬁcantly above theA+ B) and P11 (C + D). Primary human erythroid cultures were divided into responders
centage as determined byHPLC analysis following treatment. The results are the average of
n HbF levels according to the paired t-test (p-value b 0.05), are marked with *.
Fig. 4. Treatment of primary human erythroid cultures from healthy donorswith P4. Primary erythroid cultures were divided into responders (A) and non-responders (B) based on a 10%
increase threshold in HbF percentage as determined by HPLC analysis. The results are the average of 4–8 cultures. Error bars correspond to the standard deviation. Statistically signiﬁcant
changes in cell survival according to the paired t-test (p-value b 0.05) above the vehicle treated cells are marked with *.
Fig. 5.Dual treatment with resveratrol and decitabine in K562 cells. Cell survival (A) and hemoglobin induction (B) weremeasured for each agent alone and in combination with the sec-
ond agent. A signiﬁcant increase in hemoglobin production (p-value b 0.05, paired t-test) was observed between the combinatorial regime and both concentrations of resveratrol alone,
but not signiﬁcantly above any of the concentrations of decitabine alone. Cytotoxicity was not statistically increased above the additive effect of the agents and was only occasionally sig-
niﬁcantly (p-value b 0.05) increased above the toxicity of each agent alone. The results represent the average of three experimentswith error bars corresponding to the standarddeviation.
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resveratrol tested. Although the increase of hemoglobin production
with the combined regime was higher than the effect of decitabine
alone, this increase was not statistically signiﬁcantly (p-value N 0.05)
above the effect of decitabine alone. In particular, the strongest response
was obtainedwhen100 nMdecitabinewas administeredwith 5 μMres-
veratrol, resulting in a 6.5 fold increase in the percentage of hemoglobin
containing cells, an increase that was signiﬁcantly higher than the 1.83-
fold increase observed with resveratrol alone and non-signiﬁcantly
higher than the 5.2 increase observed with decitabine alone (Fig. 5).
However, the combinatorial effect observed was signiﬁcantly lower
than the additive effect of both agents together at all concentrations
tested (p-value b 0.05, paired t-test), suggesting competition between
the two agents for common down-stream targets or saturation of com-
mon targets. Additionally, the cytotoxicity of the combinatorial regime
was not signiﬁcantly different from the additive toxicity of the two
agents alone (p-value N 0.05, paired t-test) and only occasionally signif-
icantly greater than the cytotoxicity of each agent (p-value b 0.05,
paired t-test). Despite the fact that the combined therapy increased he-
moglobin production below the additive effect of the agents, the small
increase above the effect of each agent alone and the lack of major in-
crease in cytotoxicity, still renders this approach as beneﬁcial.
4. Discussion
A number of studies have led to the identiﬁcation of different classes
of pharmacological agents able to reactivate HbF synthesis both in vitro
and in vivo. For many of these chemicals, however, there are concerns
over their toxic and carcinogenic potential in humans. Studies have
shown that resveratrol not only exhibits antioxidant activity, but can
also stimulate the expression of the γ-globin genes [34]. In the current
study, we have shown that resveratrol can increase hemoglobin pro-
duction in K562 cells. However, increasing concentrations of resveratrol
in K562 cells resulted in a dose-dependent reduction in cell survival
conﬁrming its anti-proliferative effect, possibly mediated through cell
cycle arrest and induction of ER stress as shown by Liu et al. [41]. Due
to this anti-proliferative effect, identiﬁcation of resveratrol derivatives
which exhibit potent hemoglobin-inducing properties with lower cyto-
toxicity is important. In an effort to identify such compounds, nine novel
resveratrol derivativeswere synthesized and tested in K562 cells. Out of
these, only three derivatives (P1, P4 and P11) exhibited hemoglobin in-
ducing activity comparable to the parent compound in K562 cells, with
only one (P11) being less cytotoxic. Although previous studies [34] have
shown that resveratrol also has an effective HbF inducing activity in pri-
mary human erythroid cultures, our results show that none of the
agents tested, including resveratrol, have a uniformly potent HbF induc-
ing activity in all the primary human erythroid cultures tested. For each
agent tested, some cultures responded quite strongly, in terms of in-
crease in the levels of HbF, while others responded poorly. Therefore,
cultures were grouped into responders and non-responders based on
their HbF increase following induction with each agent. Resveratrol
and derivative P11 showed a statistically signiﬁcant increase in HbF
levels, within the responder group, at 1 and 0.01 μM concentrations, re-
spectively. In contrast, both agents reduced HbF levels below the levels
observed in the un-treated control, within the non-responder group.
The above ﬁndings suggest that the effectiveness of the two agents is
limited due to their lack of uniform HbF induction in primary erythroid
cultures.
The low HbF induction observed in primary human erythroid cul-
tures of responders does not coincide with the high hemoglobin-
inducing activity of resveratrol observed in K562 cells. In the K562 cell
line, resveratrol is shown to promote differentiation thatmight not nec-
essarily correspond to an increase in the percentage of HbF in primary
human erythroid cultures. In fact, Franco et al. [42] showed that resver-
atrol accelerates erythroid cell maturation of CD34+ erythrocytes from
healthy and β-thalassaemic patients, through up-regulation of FOXO3arather than increasing the expression of γ-globin gene expression. It
would therefore be interesting to investigate whether the three deriva-
tives have the ability to promote erythroid cell maturation despite the
variable effect in HbF production in primary erythroid cultures.
Furthermore, with a more optimal induction protocol the increase in
HbF production observed following the addition of test chemicals to pri-
mary culturesmight bemore signiﬁcant. Lancon et al. [43] demonstrated
that cellular uptake of resveratrol is reduced by two fold inmedium con-
taining 10% serum compared to serum-free medium. Additionally, this
group showed that increasing concentrations of BSA reduced the uptake
of resveratrol by two fold at a concentration of 3.5 g/L albumin. The pri-
mary human erythroid cells used for our screening experiments were
grown in 30% serum and 11.3 g/L BSA in Phase II. We therefore suggest
that the effect of each agent should be conﬁrmed in an alternative
ex vivo experimental model.
Despite the lack of statistically signiﬁcant HbF induction in primary
erythroid cells, P4 signiﬁcantly increased cell numbers compared to
the vehicle-treated cultures, a ﬁnding that was not observed for resver-
atrol and P11. The three derivatives, although similar in structure,
demonstrate important functional differences. One of the most easily
observable structural differences which could explain some of the bio-
logical effects seen is the lack of substituents on the aromatic ring
in the case of P4 compared to the presence of ortho, para andmeta sub-
stituents on resveratrol and the other derivatives.
Therapeutic approaches for the treatment of β-thalassemia should
be directed towards improving the clinical picture of the patients. How-
ever, most HbF inducers, including 5-azacytidine and butyrate do not
have the ability to improve the clinical picture due to their low HbF
inducing activity, cytotoxicity and side effects. We therefore moved on
to investigate the combined use of resveratrol and decitabine with the
potential of increasing the HbF inducing activity of the two agents
while combining it with resveratrol's antioxidant activity. Decitabine
is a hypomethylating agent that is known to have a chemopreventive
rather than carcinogenic effect while increasing HbF levels [44]. In
contrast, resveratrol has antioxidant activity, a crucial property in
beta-thalassemia, and can inhibit ribonucleotide reductase in a similar
manner to hydroxyurea [33]. On preliminary screening on K562 cells
we have shown that a combinatorial regime of 5 μM resveratrol and
100 nM decitabine increases the percentage of hemoglobin producing
cells by 6.5 fold. The increase in hemoglobin containing cellswas greater
than the effect observed using each agent alone, butwas only statistical-
ly signiﬁcantly elevated above the effect of resveratrol alone. Moreover,
the increase observed with the combinatorial regime is lower than the
additive effect of the two agents suggesting competition between the
two agents for common down-stream targets or saturation of common
targets. Despite the minimal synergistic induction in hemoglobin pro-
duction offered by the combinatorial regime in K562 cells, the combina-
tion should be investigated further in primary human erythroid cultures
and thalassemic mouse models to study the effect of the combinatorial
therapy speciﬁcally on HbF levels and the phenotypic picture of the
disease, respectively. The use of a combinatorial approach as a method
for pharmacological reactivation of HbF is still interesting as can be
seen by the increase in HbF levels in CD34+ erythrocytes when treated
with pomalidomide and HU [40]. Furthermore, studies regarding the
HbF inducing activity of resveratrol are still controversial and thus
further investigation of resveratrol and its derivatives as a therapeutic
approach of β-thalassemia is indicated.
In conclusion, we have shown that three resveratrol derivatives can
increase the percentage of hemoglobin containing cells in K562 cell line
with P11 being less cytotoxic than resveratrol. A respective increase in
the levels of HbF was replicated only in a small number of primary
human erythroid cultures derived from healthy volunteers suggesting
a variable response to the agents. Further investigation of resveratrol
and its derivatives is encouraged in different experimental models. In
addition, the synergistic effect of resveratrol and decitabine on hemo-
globin production was only minimal in K562 cells.
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